ERBB2 and breast cancer: Using DISVT, we demonstrated that DISVT, but not ELISA, detected human epidermal growth factor receptor 2 (HER2)-positive breast cancer by quantification of HER2-positive EVs among the CD81-positive plasmon EVs.